|
1
|
Schuette W: Treatment of brain metastases
from lung cancer: Chemotherapy. Lung Cancer. 45(Suppl 2):
S253–S257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khalifa J, Amini A, Popat S, Gaspar LE and
Faivre-Finn C: International Association for the Study of Lung
Cancer Advanced Radiation Technology C: Brain metastases from
NSCLC: Radiation therapy in the Era of targeted therapies. J Thorac
Oncol. 11:1627–1643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Langer CJ and Mehta MP: Current management
of brain metastases, with a focus on systemic options. J Clin
Oncol. 23:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Owen S and Souhami L: The management of
brain metastases in non-small cell lung cancer. Front Oncol.
4:2482014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Antonio C, Passaro A, Gori B, Del
Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F:
Bone and brain metastasis in lung cancer: Recent advances in
therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lagerwaard FJ, Levendag PC, Nowak PJ,
Eijkenboom WM, Hanssens PE and Schmitz PI: Identification of
prognostic factors in patients with brain metastases: A review of
1292 patients. Int J Radiat Oncol Biol Phys. 43:795–803. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi AA, Digumarthy SR, Temel JS, Halpern
EF, Kuester LB and Aquino SL: Does initial staging or tumor
histology better identify asymptomatic brain metastases in patients
with non-small cell lung cancer? J Thorac Oncol. 1:205–210. 2006.
View Article : Google Scholar
|
|
8
|
Mujoomdar A, Austin JH, Malhotra R, Powell
CA, Pearson GD, Shiau MC and Raftopoulos H: Clinical predictors of
metastatic disease to the brain from non-small cell lung carcinoma:
Primary tumor size, cell type, and lymph node metastases.
Radiology. 242:882–888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shin DY, Na II, Kim CH, Park S, Baek H and
Yang SH: EGFR mutation and brain metastasis in pulmonary
adenocarcinomas. J Thorac Oncol. 9:195–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fallet V, Cadranel J, Doubre H, Toper C,
Monnet I, Chinet T, Oliviero G, Foulon G, De Cremoux H, Vieira T,
et al: Prospective screening for ALK: Clinical features and outcome
according to ALK status. Eur J Cancer. 50:1239–1246. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heigener DF, Kerr KM, Laing GM, Mok TSK,
Moiseyenko FV and Reck M: Redefining treatment paradigms in
first-line advanced non-small-cell lung cancer. Clin Cancer Res.
25:4881–4887. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brastianos PK, Carter SL, Santagata S,
Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS,
Horowitz PM, Cibulskis K, et al: Genomic characterization of brain
metastases reveals branched evolution and potential therapeutic
targets. Cancer Discov. 5:1164–1177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack
I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR,
Chukwueke U, et al: Genomic characterization of human brain
metastases identifies drivers of metastatic lung adenocarcinoma.
Nat Genet. 52:371–377. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandes Marques J, Pereira Reis J,
Fernandes G, Hespanhol V, Machado JC and Costa JL: Circulating
tumor DNA: A step into the future of cancer management. Acta Cytol.
63:456–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jahr S, Hentze H, Englisch S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.PubMed/NCBI
|
|
17
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Keller L and Pantel K: Unravelling tumour
heterogeneity by single-cell profiling of circulating tumour cells.
Nat Rev Cancer. 19:553–567. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murtaza M, Dawson SJ, Pogrebniak K, Rueda
OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, et
al: Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
6:87602015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marusyk A, Janiszewska M and Polyak K:
Intratumor heterogeneity: The Rosetta stone of therapy resistance.
Cancer Cell. 37:471–484. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rolfo C, Mack PC, Scagliotti GV, Baas P,
Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al:
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A
statement paper from the IASLC. J Thorac Oncol. 13:1248–1268. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen G, Cai Z, Li Z, Dong X, Xu H, Lin J,
Chen L, Zhang H, Liu X and Liu J: Clonal evolution in long-term
follow-up patients with hepatocellular carcinoma. Int J Cancer.
143:2862–2870. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gandevia B and Tovell A: Declaration of
Helsinki. Med J Aust. 2:320–321. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H and Durbin R: Fast and accurate
long-read alignment with Burrows-Wheeler transform. Bioinformatics.
26:589–595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lai Z, Markovets A, Ahdesmaki M, Chapman
B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC and Dry
JR: VarDict: A novel and versatile variant caller for
next-generation sequencing in cancer research. Nucleic Acids Res.
44:e1082016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang K, Li M and Hakonarson H: ANNOVAR:
functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Adzhubei IA, Schmidt S, Peshkin L,
Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A
method and server for predicting damaging missense mutations. Nat
Methods. 7:248–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwarz JM, Rodelsperger C, Schuelke M and
Seelow D: MutationTaster evaluates disease-causing potential of
sequence alterations. Nat Methods. 7:575–576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin JJ, Riely GJ and Shaw AT: Targeting
ALK: Precision medicine takes on drug resistance. Cancer Discov.
7:137–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Holla VR, Elamin YY, Bailey AM, Johnson
AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA,
Shaw KR, et al: ALK: A tyrosine kinase target for cancer therapy.
Cold Spring Harb Mol Case Stud. 3:a0011152017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Camidge DR, Kim DW, Tiseo M, Langer CJ,
Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, et
al: Exploratory analysis of brigatinib activity in patients with
anaplastic lymphoma kinase-positive non-small-cell lung cancer and
brain metastases in two clinical trials. J Clin Oncol.
36:2693–2701. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gadgeel SM, Gandhi L, Riely GJ, Chiappori
AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, et al:
Safety and activity of alectinib against systemic disease and brain
metastases in patients with crizotinib-resistant ALK-rearranged
non-small-cell lung cancer (AF-002JG): Results from the
dose-finding portion of a phase 1/2 study. Lancet Oncol.
15:1119–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tomasini P, Egea J, Souquet-Bressand M,
Greillier L and Barlesi F: Alectinib in the treatment of
ALK-positive metastatic non-small cell lung cancer: Clinical trial
evidence and experience with a focus on brain metastases. Ther Adv
Respir Dis. Feb 21–2019.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Solomon BJ, Besse B, Bauer TM, Felip E,
Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, et al:
Lorlatinib in patients with ALK-positive non-small-cell lung
cancer: Results from a global phase 2 study. Lancet Oncol.
19:1654–1667. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Naito T, Shiraishi H and Fujiwara Y:
Brigatinib and lorlatinib: Their effect on ALK inhibitors in NSCLC
focusing on resistant mutations and central nervous system
metastases. Jpn J Clin Oncol. 51:37–44. 2021. View Article : Google Scholar
|
|
40
|
Chao D, Pang L, Shi Y, Wang W and Liu K:
AZD3759 induces apoptosis in hepatoma cells by activating a
p53-SMAD4 positive feedback loop. Biochem Biophys Res Commun.
509:535–540. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hochmair M: Medical treatment options for
patients with epidermal growth factor receptor mutation-positive
non-small cell lung cancer suffering from brain metastases and/or
leptomeningeal disease. Target Oncol. 13:269–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lorenzetto E, Brenca M, Boeri M, Verri C,
Piccinin E, Gasparini P, Facchinetti F, Rossi S, Salvatore G,
Massimino M, et al: YAP1 acts as oncogenic target of 11q22
amplification in multiple cancer subtypes. Oncotarget. 5:2608–2621.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao
JH, Tetsu O, Li H, Jablons DM and You L: Inhibition of ERK1/2
down-regulates the Hippo/YAP signaling pathway in human NSCLC
cells. Oncotarget. 6:4357–4368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cheng H, Zhang Z, Rodriguez-Barrueco R,
Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R and
Halmos B: Functional genomics screen identifies YAP1 as a key
determinant to enhance treatment sensitivity in lung cancer cells.
Oncotarget. 7:28976–28988. 2016. View Article : Google Scholar :
|
|
45
|
Hsu PC, You B, Yang YL, Zhang WQ, Wang YC,
Xu Z, Dai Y, Liu S, Yang CT, Li H, et al: YAP promotes erlotinib
resistance in human non-small cell lung cancer cells. Oncotarget.
7:51922–51933. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hsu PC, Miao J, Huang Z, Yang YL, Xu Z,
You J, Dai Y, Yeh CC, Chan G, Liu S, et al: Inhibition of
yes-associated protein suppresses brain metastasis of human lung
adenocarcinoma in a murine model. J Cell Mol Med. 22:3073–3085.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Villa E, Ali ES, Sahu U and Ben-Sahra I:
Cancer cells tune the signaling pathways to empower de novo
synthesis of nucleotides. Cancers(Basel). 11:6882019.
|
|
48
|
Buj R and Aird KM: Deoxyribonucleotide
triphosphate metabolism in cancer and metabolic disease. Front
Endocrinol (Lausanne). 9:1772018. View Article : Google Scholar
|
|
49
|
Shiotani T, Hashimoto Y, Fujita J,
Yamauchi N, Yamaji Y, Futami H, Bungo M, Nakamura H, Tanaka T and
Irino S: Reversal of enzymic phenotype of thymidine metabolism in
induced differentiation of U-937 cells. Cancer Res. 49:6758–6763.
1989.PubMed/NCBI
|
|
50
|
Hanssen A, Riebensahm C, Mohme M, Joosse
SA, Velthaus JL, Berger LA, Bernreuther C, Glatzel M, Loges S,
Lamszus K, et al: Frequency of circulating tumor cells (CTC) in
patients with brain metastases: Implications as a risk assessment
marker in oligo-metastatic disease. Cancers (Basel). 10:5272018.
View Article : Google Scholar
|
|
51
|
Riebensahm C, Joosse SA, Mohme M, Hanssen
A, Matschke J, Goy Y, Witzel I, Lamszus K, Kropidlowski J, Petersen
C, et al: Clonality of circulating tumor cells in breast cancer
brain metastasis patients. Breast Cancer Res. 21:1012019.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ye Y, Luo Z and Shi D: Use of cell free
DNA as a prognostic biomarker in non-small cell lung cancer
patients with bone metastasis. Int J Biol Markers. 34:381–388.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aldea M, Hendriks L, Mezquita L, Jovelet
C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A,
et al: Circulating tumor DNA analysis for patients with
oncogene-addicted NSCLC with isolated central nervous system
progression. J Thorac Oncol. 15:383–391. 2020. View Article : Google Scholar
|
|
54
|
Gedvilaite V, Schveigert D and Cicenas S:
Cell-free DNA in non-small cell lung cancer. Acta Med Litu.
24:138–144. 2017.PubMed/NCBI
|
|
55
|
Nygaard AD, Garm Spindler KL, Pallisgaard
N, Andersen RF and Jakobsen A: The prognostic value of KRAS mutated
plasma DNA in advanced non-small cell lung cancer. Lung Cancer.
79:312–317. 2013. View Article : Google Scholar
|
|
56
|
Aggarwal C, Thompson JC, Black TA, Katz
SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, et al:
Clinical implications of plasma-based genotyping with the delivery
of personalized therapy in metastatic non-small cell lung cancer.
JAMA Oncol. 5:173–180. 2019. View Article : Google Scholar
|
|
57
|
Mack PC, Banks KC, Espenschied CR, Burich
RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB
and Gandara DR: Spectrum of driver mutations and clinical impact of
circulating tumor DNA analysis in non-small cell lung cancer:
Analysis of over 8000 cases. Cancer. 126:3219–3228. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Adzhubei I, Jordan DM and Sunyaev SR:
Predicting functional effect of human missense mutations using
PolyPhen-2. Curr Protoc Hum Genet. Chapter 7: Unit7 20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
1000 Genomes Project Consortium; Auton A,
Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL,
McCarthy S, McVean GA and Abecasis GR: A global reference for human
genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kircher M, Witten DM, Jain P, O'Roak BJ,
Cooper GM and Shendure J: A general framework for estimating the
relative pathogenicity of human genetic variants. Nat Genet.
46:310–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ng PC and Henikoff S: SIFT: Predicting
amino acid changes that affect protein function. Nucleic Acids Res.
31:3812–3814. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
McNulty SN, Parikh BA, Duncavage EJ,
Heusel JW and Pfeifer JD: Optimization of population frequency
cutoffs for filtering common germline polymorphisms from tumor-only
next-generation sequencing data. J Mol Diagn. 21:903–912. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sukhai MA, Misyura M, Thomas M, Garg S,
Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, et al:
Somatic tumor variant filtration strategies to optimize tumor-only
molecular profiling using targeted next-generation sequencing
panels. J Mol Diagn. 21:261–273. 2019. View Article : Google Scholar
|
|
64
|
Hiltemann S, Jenster G, Trapman J, van der
Spek P and Stubbs A: Discriminating somatic and germline mutations
in tumor DNA samples without matching normals. Genome Res.
25:1382–1390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Teer JK, Zhang Y, Chen L, Welsh EA, Cress
WD, Eschrich SA and Berglund AE: Evaluating somatic tumor mutation
detection without matched normal samples. Hum Genomics. 11:222017.
View Article : Google Scholar : PubMed/NCBI
|
